Background: Omalizumab is not considered a disease-modifying drug and, accordingly, a large proportion of patients experience a relapse following withdrawal from treatment. Patients & methods: A total of 42 patients who underwent at least one cycle of treatment with omalizumab were enrolled. Two groups of relapsed and not-relapsed subjects were compared. Then, patients were divided into subgroups. Results: Female patients relapse more frequently than male subjects. Patients who relapsed complained a long duration of disease, while patients who did not relapse had short a history of disease. Very early responders are thought to have a high recurrence rate. Basal IgE levels were increased in early responders and cholesterol levels were high in very early responders, who relapse following withdrawal from omalizumab. High D-dimer levels were observed in late responders. Conclusion: The identification of clinical and serological predictors will play a pivotal role in the future management of patients treated with omalizumab.
Background: Omalizumab is not considered a disease-modifying drug and, accordingly, a large proportion of patients experience a relapse following withdrawal from treatment. Patients & methods: A total of 42 patients who underwent at least one cycle of treatment with omalizumab were enrolled. Two groups of relapsed and not-relapsed subjects were compared. Then, patients were divided into subgroups. Results: Female patients relapse more frequently than male subjects. Patients who relapsed complained a long duration of disease, while patients who did not relapse had short a history of disease. Very early responders are thought to have a high recurrence rate. Basal IgE levels were increased in early responders and cholesterol levels were high in very early responders, who relapse following withdrawal from omalizumab. High D-dimer levels were observed in late responders. Conclusion: The identification of clinical and serological predictors will play a pivotal role in the future management of patients treated with omalizumab.
Authors: Sabine Altrichter; Jie Shen Fok; Qingqing Jiao; Pavel Kolkhir; Polina Pyatilova; Sherezade Moñino Romero; Jörg Scheffel; Frank Siebenhaar; Carolin Steinert; Dorothea Terhorst-Molawi; Yi Kui Xiang; Martin K Church; Marcus Maurer Journal: Allergy Asthma Immunol Res Date: 2021-03 Impact factor: 5.764
Authors: Maria Maddalena Sirufo; Enrica Maria Bassino; Francesca De Pietro; Lia Ginaldi; Massimo De Martinis Journal: Int J Immunopathol Pharmacol Date: 2021 Jan-Dec Impact factor: 3.219